NWPHF OTC
Newron Pharmaceuticals S.p.A.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
$20.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$51M
+467.4% ▲
5Y CAGR: +48.8%
Gross Profit
$51M
+467.4% ▲
5Y CAGR: +55.7%
Operating Income
$26M
+325.1% ▲
Net Income
$16M
+197.7% ▲
EPS (Diluted)
$0.85
+193.4% ▲
EBITDA
$26M
+319.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $5M | $6M | $6M | $9M | $51M |
| YoY Growth | -25.3% | +9.6% | +5.8% | +48.6% | +467.4% |
| Cost of Revenue | $295K | $0 | $0 | $0 | $0 |
| Gross Profit | $5M | $6M | $6M | $9M | $51M |
| Gross Margin | 94.4% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D Expenses | $16M | $11M | $12M | $13M | $14M |
| SG&A Expenses | $8M | $4M | $4M | $4M | $7M |
| Operating Expenses | $23M | $18M | $20M | $21M | $25M |
| Operating Income | -$18M | -$12M | -$13M | -$12M | $26M |
| Operating Margin | -343.6% | -214.5% | -218.3% | -128.4% | 50.9% |
| Interest Expense | $2M | $3M | $4M | $4M | $4M |
| Income Before Tax | -$20M | -$15M | -$17M | -$16M | $21M |
| Tax Expense | $1M | $17K | $21K | $24K | $6M |
| Net Income | -$21M | -$15M | -$17M | -$16M | $16M |
| Net Margin | -399.4% | -258.6% | -287.1% | -179.1% | 30.8% |
| EPS (Diluted) | $-1.18 | $-0.84 | $-0.98 | $-0.91 | $0.85 |
| EBITDA | -$17M | -$12M | -$13M | -$12M | $26M |
| Shares Outstanding | 18M | 18M | 18M | 18M | 19M |